Occult cancer and thromboembolism: current epidemiology and its practical implication

Chao, Chia-Ter; Wang, Hsin‐Yi; Kao, Chia‐Hung

doi:10.20452/pamw.4311

Cited by 6 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…79 Based on the current guidelines, about 80% of patients with AF and cancer had indica tions for chronic anticoagulation. 80 Of note, can cer is associated with an increased risk of bleed ing related to thrombocytopenia, metastases, kid ney and liver damage, vessel damage caused by a tumor infiltrating its wall, invasive procedures, and radiation therapy. 69 Regarding patients with cancer and AF, most data are from observational studies.…”

Section: Scoring Systems To Predict Bleeding In Atrial Fibrillationmentioning

confidence: 99%

Bleeding in anticoagulated patients with atrial fibrillation: practical considerations

Undas

Drabik

Potpara

2020

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Bleeding in anticoagulated patients with AF: practical considerations 47 controlled trials (RCTs), NOACs reduced the risk of stroke or SE by 19% compared with warfarin (relative risk [RR], 0.81; 95% CI, 0.73-0.91), large ly due to a markedly lower rate of hemorrhagic strokes (RR 0.49, 95% CI, 0.38-0.64) and intracra nial bleeding (ICB) (RR, 0.48; 95% CI, 0.39-0.59). 9 However, the use of NOACs (in particular, full dose dabigatran and rivaroxaban) was signifi cantly associated with an increased risk of gas trointestinal (GI) bleeding (RR, 1.25; 95% CI, 1.01-1.55). 7 Of note, the differences between baseline stroke and bleeding risks among differ ent NOAC trials could have affected the report ed bleeding rates (FIguRE 1). Residual incidence of stroke or SE despite NOAC use among pa tients with AF is estimated at 1.5% to 2.5% per year and that of major bleeding at 2% to 4% per year. 9 As compared with warfarin, NOACs slight ly reduced all cause mortality (RR, 0.89; 95% CI, 0.85-0.94), vascular mortality (RR, 0.88; 95% CI, 0.82-0.94), and bleeding related mortality (RR, 0.54; 95% CI, 0.44-0.67). 10 Importantly, in the phase 3 AF trials, NOACs were more effective than warfarin in the prevention of stroke or SE among patients with AF aged 75 years or older.

show abstract

Section: Scoring Systems To Predict Bleeding In Atrial Fibrillationmentioning

confidence: 99%

Bleeding in anticoagulated patients with atrial fibrillation: practical considerations

Undas

Drabik

Potpara

2020

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…65 Cancer patients make up to 20% of all individuals with newly diagnosed VTE. 66,67 It has been suggested that clot properties, including impaired fibrinolysis, can be useful in identifying VTE patients at risk of developing or detecting malignant diseases following a negative initial standard cancer screening at VTE diagnosis. During a long-term follow-up, malignancy was diagnosed in 6% of VTE patients, who had several fibrin-related abnormalities, including impaired fibrinolysis (þ25.5% CLT) measured after a mean 4month anticoagulation had been stopped.…”

Section: Fibrinolysis Following Vtementioning

confidence: 99%

Fibrinolysis in Venous Thromboembolism

Undas

2021

Semin Thromb Hemost

View full text Add to dashboard Cite

Fibrinolysis is of paramount importance in maintaining or regaining the patency of veins and pulmonary arteries obstructed by thrombi. Growing experimental and clinical evidence indicates that impaired fibrinolysis mediated by multiple complex mechanisms is involved in venous thromboembolism (VTE). Global plasma fibrin clot lysis markers, especially clot lysis time, have been reported to predict recurrent deep-vein thrombosis and pulmonary embolism. The current overview summarizes available data linking fibrinolysis to VTE and its long-term sequelae.

show abstract

“…79 Based on the current guidelines, about 80% of patients with AF and cancer had indications for chronic anticoagulation. 80 Of note, cancer is associated with an increased risk of bleeding related to thrombocytopenia, metastases, kidney and liver damage, vessel damage caused by a tumor infiltrating its wall, invasive procedures, and radiation therapy. 69 Regarding patients with cancer and AF, most data are from observational studies.…”

Section: Specific Atrial Fibrillation Patient Populations At Risk Of mentioning

confidence: 99%

Bleeding in anticoagulated patients with atrial fibrillation: practical considerations

Undas¹,

Drabik²,

Potpara³

2020

Kardiologia Polska

View full text Add to dashboard Cite

or higher, but they are safer and more convenient. 7,8 In a meta-analysis of pivotal phase 3 AF randomized controlled trials (RCTs), NOACs reduced the risk of stroke or SE by 19% compared with warfarin (relative risk [RR], 0.81; 95% CI, 0.73-0.91), largely due to a markedly lower rate of hemorrhagic strokes (RR 0.49, 95% CI, 0.38-0.64) and intracranial bleeding (ICB) (RR, 0.48; 95% CI, 0.39-0.59). 9 However, the use of NOACs (in particular, full-dose dabigatran and rivaroxaban) was significantly associated with an increased risk of gastrointestinal (GI) bleeding (RR, 1.25; 95% CI, 1.01-1.55). 7 Of note, the differences between baseline stroke and bleeding risks among different NOAC trials could have affected the reported bleeding rates (FIGURE 1). Residual incidence of stroke or SE despite NOAC use among patients with AF is estimated at 1.5% to 2.5% per year and that of major bleeding at 2% to 4% per year. 9 As compared with warfarin, NOACs slightly reduced all-cause mortality (RR

show abstract

Occult cancer and thromboembolism: current epidemiology and its practical implication

Cited by 6 publications

References 19 publications

Bleeding in anticoagulated patients with atrial fibrillation: practical considerations

Bleeding in anticoagulated patients with atrial fibrillation: practical considerations

Fibrinolysis in Venous Thromboembolism

Bleeding in anticoagulated patients with atrial fibrillation: practical considerations

Contact Info

Product

Resources

About